Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRY

2004; Lippincott Williams & Wilkins; Volume: 171; Issue: 4 Linguagem: Inglês

10.1097/01.ju.0000107247.81471.06

ISSN

1527-3792

Autores

Matthew R. Cooperberg, Jeanette M. Broering, Mark S. Litwin, Deborah P. Lubeck, S. Mehta, James M. Henning, Peter R. Carroll,

Tópico(s)

Bladder and Urothelial Cancer Treatments

Resumo

No AccessJournal of UrologyCLINICAL UROLOGY: Review Article1 Apr 2004THE CONTEMPORARY MANAGEMENT OF PROSTATE CANCER IN THE UNITED STATES: LESSONS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR (CAPSURE), A NATIONAL DISEASE REGISTRY MATTHEW R. COOPERBERG, JEANETTE M. BROERING, MARK S. LITWIN, DEBORAH P. LUBECK, SHILPA S. MEHTA, JAMES M. HENNING, PETER R. CARROLL, and the CaPSURE INVESTIGATORS MATTHEW R. COOPERBERGMATTHEW R. COOPERBERG , JEANETTE M. BROERINGJEANETTE M. BROERING , MARK S. LITWINMARK S. LITWIN , DEBORAH P. LUBECKDEBORAH P. LUBECK , SHILPA S. MEHTASHILPA S. MEHTA , JAMES M. HENNINGJAMES M. HENNING , PETER R. CARROLLPETER R. CARROLL , and the CaPSURE INVESTIGATORS View All Author Informationhttps://doi.org/10.1097/01.ju.0000107247.81471.06AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The epidemiology and treatment of prostate cancer have changed dramatically in the prostate specific antigen era. A large disease registry facilitates the longitudinal observation of trends in disease presentation, management and outcomes. Materials and Methods: The Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a national disease registry of more than 10,000 men with prostate cancer accrued at 31 primarily community based sites across the United States. Demographic, clinical, quality of life and resource use variables are collected on each patient. We reviewed key findings from the data base in the last 8 years in the areas of disease management trends, and oncological and quality of life outcomes. Results: Prostate cancer is increasingly diagnosed with low risk clinical characteristics. With time patients have become less likely to receive pretreatment imaging tests, less likely to pursue watchful waiting and more likely to receive brachytherapy or hormonal therapy. Relatively few patients treated with radical prostatectomy in the database are under graded or under staged before surgery, whereas the surgical margin rate is comparable to that in academic series. CaPSURE data confirm the usefulness of percent positive biopsies in risk assessment and they have further been used to validate multiple preoperative nomograms. CaPSURE results strongly affirm the necessity of patient reported quality of life assessment. Multiple studies have compared the quality of life impact of various treatment options, particularly in terms of urinary and sexual function, and bother. Conclusions: The presentation and management of prostate cancer have changed substantially in the last decade. CaPSURE will continue to track these trends as well as oncological and quality of life outcomes, and will continue to be an invaluable resource for the study of prostate cancer at the national level. References 1 : Cancer statistics, 2003. CA Cancer J Clin2003; 53: 5. Google Scholar 2 : Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer2001; 96: 363. Google Scholar 3 Stanford J.L., Stephenson R.A., Coyle L.M., Cerhan J., Correa R., Eley J.W. et-al.: Prostate Cancer Trends 1973–1995, SEER Program. Bethesda, Maryland: National Cancer Institute, National Institute of Health Publication No. 99–4543, 1999 Google Scholar 4 : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med2002; 347: 781. Google Scholar 5 : Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment?. Urology1995; 46: 77. Google Scholar 6 : An analysis of watchful waiting for clinically localized prostate cancer. J Urol1998; 159: 1431. Link, Google Scholar 7 : Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol2002; 20: 557. Google Scholar 8 : Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology1999; 54: 424. Google Scholar 9 : The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care1992; 30: 473. Google Scholar 10 : The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care1998; 36: 1002. Google Scholar 11 : Older patients' health status and satisfaction with medical care in an HMO population. Med Care1990; 28: 261. Google Scholar 12 : An instrument to measure patient satisfaction with healthcare in an observational database: results of a validation study using data from CaPSURE. Am J Manag Care2000; 6: 70. Google Scholar 13 : Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer1994; 73: 2791. Google Scholar 14 : The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel Cancer of the Prostate Strategic Urologic Research Endeavor. Urology1996; 48: 773. Google Scholar 15 : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998; 280: 969. Google Scholar 16 : Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol2003; 170: 905. Link, Google Scholar 17 : Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol2003; 170: S21. Link, Google Scholar 18 : Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?. Cancer2002; 94: 2282. Google Scholar 19 : Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. J Urol1998; 160: 2102. Link, Google Scholar 20 : Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am1993; 20: 705. Google Scholar 21 : Contemporary trends in imaging test utilization for prostate cancer staging: data from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol2002; 168: 491. Link, Google Scholar 22 : Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol2002; 167: 1231. Link, Google Scholar 23 : PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys2001; 50: 615. Google Scholar 24 : Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from the CaPSURE database. J Urol2000; 164: 81. Link, Google Scholar 25 : Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol2003; 170: 1804. Link, Google Scholar 26 : The changing face of low-risk prostate cancer: trends in clinical presentation and treatment patterns (data from CaPSURE). J Urol2003; 169: 459. abstract 1723. Google Scholar 27 : National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst2003; 95: 981. Google Scholar 28 : Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology2001; 57: 499. Google Scholar 29 : Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol2001; 165: 851. Link, Google Scholar 30 : 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol1994; 152: 1837. Link, Google Scholar 31 : Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol1994; 152: 1831. Link, Google Scholar 32 : Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol1994; 152: 1850. Link, Google Scholar 33 : Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol1997; 21: 566. Google Scholar 34 : Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am1996; 23: 651. Google Scholar 35 : Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol1996; 20: 286. Google Scholar 36 : Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol1995; 154: 1818. Link, Google Scholar 37 : A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol1995; 154: 131. Link, Google Scholar 38 : Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol2000; 163: 1171. Link, Google Scholar 39 : Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology1998; 52: 1079. Google Scholar 40 : Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol2000; 18: 1164. Google Scholar 41 : Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol2002; 167: 516. Link, Google Scholar 42 : Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology2002; 59: 560. Google Scholar 43 : The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol1993; 150: 110. Abstract, Google Scholar 44 : Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol2000; 164: 1591. Link, Google Scholar 45 : How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the Cancer of the Prostate Strategic Urological Research Endeavor. J Urol2002; 167: 1653. Link, Google Scholar 46 : Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol1998; 159: 929. Link, Google Scholar 47 : Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol2001; 166: 1322. Link, Google Scholar 48 : A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst1998; 90: 766. Google Scholar 49 : International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol2002; 20: 3206. Google Scholar 50 : Validation of the Kattan pre-treatment nomogram in community patients undergoing radical prostatectomy: results from CaPSURE. J Urol2003; 169: 444. abstract 1661. Google Scholar 51 : Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol2003; 169: 157. Link, Google Scholar 52 : Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy?. J Urol2002; 168: 2510. Link, Google Scholar 53 : A surrogate marker for prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy. J Urol2003; 169: 458. abstract 1716. Google Scholar 54 : Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA1998; 280: 975. Google Scholar 55 : Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Qual Life Res1997; 6: 385. Google Scholar 56 : Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. Eur J Cancer1990; 26: 1133. Google Scholar 57 : Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol1998; 159: 1988. Link, Google Scholar 58 : How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE. Urology2003; 61: 190. Google Scholar 59 : Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr1988; 7: 47. Google Scholar 60 : Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer. Int J Radiat Oncol Biol Phys1997; 37: 551. Google Scholar 61 : Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998; 51: 991. Google Scholar 62 : Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys1999; 43: 735. Google Scholar 63 : Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology1993; 42: 622. Google Scholar 64 : Erectile functioning of men treated for prostate carcinoma. Cancer1997; 79: 538. Google Scholar 65 : 'Potency': the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability. Br J Urol1998; 81: 135. Google Scholar 66 NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA1993; 270: 83. Google Scholar 67 : Quality-of-life outcomes in men treated for localized prostate cancer. JAMA1995; 273: 129. Google Scholar 68 : Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol1995; 154: 1420. Link, Google Scholar 69 : Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology1999; 53: 180. Google Scholar 70 : Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol2000; 164: 1973. Link, Google Scholar 71 : Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology1999; 54: 503. Google Scholar 72 : Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol1998; 16: 275. Google Scholar 73 : Health related quality of life differences between black and white men with prostate cancer: data from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol2001; 166: 2281. Link, Google Scholar 74 : The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol2001; 54: 350. Google Scholar From the Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco/Mt. Zion Comprehensive Cancer Center, University of California-San Francisco (MRC, JMB, DPL, PRC), San Francisco, the David Geffen School of Medicine and School of Public Health, University of California-Los Angeles (MSL), Los Angeles, California, and TAP Pharmaceutical Products, Inc. (SSM, JMH), Lake Forest, Illinois© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byLonergan P, Washington S, Cowan J, Zhao S, Broering J, Cooperberg M and Carroll P (2021) Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate CancerJournal of Urology, VOL. 207, NO. 4, (832-840), Online publication date: 1-Apr-2022.Luckenbaugh A, Wallis C, Huang L, Wittmann D, Klaassen Z, Zhao Z, Koyama T, Laviana A, Conwill R, Goodman M, Hamilton A, Wu X, Paddock L, Stroup A, Cooperberg M, Hashibe M, O'Neil B, Kaplan S, Greenfield S, Hoffman K, Penson D and Barocas D (2022) Association between Treatment for Localized Prostate Cancer and Mental Health OutcomesJournal of Urology, VOL. 207, NO. 5, (1029-1037), Online publication date: 1-May-2022.Zuniga K, Zhao S, Kenfield S, Cedars B, Cowan J, Van Blarigan E, Broering J, Carroll P and Chan J (2019) Trends in Complementary and Alternative Medicine Use among Patients with Prostate CancerJournal of Urology, VOL. 202, NO. 4, (689-695), Online publication date: 1-Oct-2019.Griebling T (2018) Re: Patients Receiving Androgen Deprivation Therapy for Prostate Cancer Have an Increased Risk of Depressive DisorderJournal of Urology, VOL. 200, NO. 2, (223-223), Online publication date: 1-Aug-2018.Eifler J, Alvarez J, Koyama T, Conwill R, Ritch C, Hoffman K, Resnick M, Penson D and Barocas D (2016) More Judicious Use of Expectant Management for Localized Prostate Cancer during the Last 2 DecadesJournal of Urology, VOL. 197, NO. 3 Part 1, (614-620), Online publication date: 1-Mar-2017.Vertosick E, Vickers A, Cowan J, Broering J, Carroll P and Cooperberg M (2018) Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated InstrumentsJournal of Urology, VOL. 198, NO. 3, (671-677), Online publication date: 1-Sep-2017.Hussein A, Punnen S, Zhao S, Cowan J, Leapman M, Tran T, Washington S, Truesdale M, Carroll P and Cooperberg M (2018) Current Use of Imaging after Primary Treatment of Prostate CancerJournal of Urology, VOL. 194, NO. 1, (98-104), Online publication date: 1-Jul-2015.Tomaszewski J, Richman E, Sadetsky N, O'Keefe D, Carroll P, Davies B and Chan J (2018) Impact of Folate Intake on Prostate Cancer Recurrence Following Definitive Therapy: Data from CaPSURE™Journal of Urology, VOL. 191, NO. 4, (971-976), Online publication date: 1-Apr-2014.Hussein A, Welty C, Broering J, Cooperberg M and Carroll P (2018) National Prostate Cancer Registries: Contemporary Trends of Prostate Cancer in the United StatesUrology Practice, VOL. 1, NO. 4, (198-204), Online publication date: 1-Nov-2014.Carlsson S, Ehdaie B, Atoria C, Elkin E and Eastham J (2018) Risk of Incisional Hernia after Minimally Invasive and Open Radical ProstatectomyJournal of Urology, VOL. 190, NO. 5, (1757-1762), Online publication date: 1-Nov-2013.Hoffman K, Nguyen P, Chen M, Chen R, Choueiri T, Hu J, Kuban D and D'Amico A (2018) Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized TrialsJournal of Urology, VOL. 185, NO. 1, (116-120), Online publication date: 1-Jan-2011.Yee D, Shariat S, Lowrance W, Sterbis J, Vora K, Bochner B, Donat S, Herr H, Dalbagni G and Sandhu J (2018) Impact of Previous Radiotherapy for Prostate Cancer on Clinical Outcomes of Patients With Bladder CancerJournal of Urology, VOL. 183, NO. 5, (1751-1756), Online publication date: 1-May-2010.Bañez L, Sun L, van Leenders G, Wheeler T, Bangma C, Freedland S, Ittmann M, Lark A, Madden J, Hartman A, Weiss G and Castaños-Vélez E (2018) Multicenter Clinical Validation of PITX2 Methylation as a Prostate Specific Antigen Recurrence Predictor in Patients With Post-Radical Prostatectomy Prostate CancerJournal of Urology, VOL. 184, NO. 1, (149-156), Online publication date: 1-Jul-2010.Reese A, Cooperberg M and Carroll P (2018) Minimal Impact of Clinical Stage on Prostate Cancer Prognosis Among Contemporary Patients With Clinically Localized DiseaseJournal of Urology, VOL. 184, NO. 1, (114-119), Online publication date: 1-Jul-2010.Loblaw A, Zhang L, Lam A, Nam R, Mamedov A, Vesprini D and Klotz L (2018) Comparing Prostate Specific Antigen Triggers for Intervention in Men With Stable Prostate Cancer on Active SurveillanceJournal of Urology, VOL. 184, NO. 5, (1942-1946), Online publication date: 1-Nov-2010.Porten S, Richardson D, Odisho A, McAninch J, Carroll P and Cooperberg M (2018) Disproportionate Presentation of High Risk Prostate Cancer in a Safety Net Health SystemJournal of Urology, VOL. 184, NO. 5, (1931-1936), Online publication date: 1-Nov-2010.Tareen B, Godoy G, Sankin A, Temkin S, Lepor H and Taneja S (2018) Laterality Alone Should Not Drive Selection of Candidates for Hemi-Ablative Focal TherapyJournal of Urology, VOL. 181, NO. 3, (1082-1090), Online publication date: 1-Mar-2009.Thompson I, Tangen C, Paradelo J, Lucia M, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E and Crawford E (2018) Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical TrialJournal of Urology, VOL. 181, NO. 3, (956-962), Online publication date: 1-Mar-2009.Dall'Era M, Hosang N, Konety B, Cowan J and Carroll P (2018) Sociodemographic Predictors of Prostate Cancer Risk Category at Diagnosis: Unique Patterns of Significant and Insignificant DiseaseJournal of Urology, VOL. 181, NO. 4, (1622-1627), Online publication date: 1-Apr-2009.Shah J, McKiernan J, Elkin E, Carroll P and Meng M (2018) Prostate Biopsy Patterns in the CaPSURE Database: Evolution With Time and Impact on Outcome After ProstatectomyJournal of Urology, VOL. 179, NO. 1, (136-140), Online publication date: 1-Jan-2008.Magera J, Inman B, Slezak J, Bagniewski S, Sebo T and Myers R (2018) Increased Optical Magnification From 2.5× to 4.3× With Technical Modification Lowers the Positive Margin Rate in Open Radical Retropubic ProstatectomyJournal of Urology, VOL. 179, NO. 1, (130-135), Online publication date: 1-Jan-2008.Litwin M (2018) Commentary on Urinary and Sexual Outcomes after Radical ProstatectomyJournal of Urology, VOL. 179, NO. 5S, (S45-S46), Online publication date: 1-May-2008.Wu A, Cooperberg M, Sadetsky N and Carroll P (2018) Health Related Quality of Life in Patients Treated With Multimodal Therapy for Prostate CancerJournal of Urology, VOL. 180, NO. 6, (2415-2422), Online publication date: 1-Dec-2008.Thong A, Shikanov S, Katz M, Gofrit O, Eggener S, Zagaja G, Shalhav A and Zorn K (2018) A Single Microfocus (5% or Less) of Gleason 6 Prostate Cancer at Biopsy—Can We Predict Adverse Pathological Outcomes?Journal of Urology, VOL. 180, NO. 6, (2436-2440), Online publication date: 1-Dec-2008.Haliloglu A, Baltaci S and Yaman O (2018) Penile Length Changes in Men Treated With Androgen Suppression Plus Radiation Therapy for Local or Locally Advanced Prostate CancerJournal of Urology, VOL. 177, NO. 1, (128-130), Online publication date: 1-Jan-2007.Boorjian S, Cowan J, Konety B, DuChane J, Tewari A, Carroll P and Kane C (2018) Bladder Cancer Incidence and Risk Factors in Men With Prostate Cancer: Results From Cancer of the Prostate Strategic Urologic Research EndeavorJournal of Urology, VOL. 177, NO. 3, (883-888), Online publication date: 1-Mar-2007.Cooperberg M, Broering J, Kantoff P and Carroll P (2007) Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and TreatmentJournal of Urology, VOL. 178, NO. 3S, (S14-S19), Online publication date: 1-Sep-2007.Marr P, Elkin E, Arredondo S, Broering J, DuChane J and Carroll P (2018) Comorbidity and Primary Treatment for Localized Prostate Cancer: Data From CaPSURE™Journal of Urology, VOL. 175, NO. 4, (1326-1331), Online publication date: 1-Apr-2006.Meng M, Elkin E, DuChane J and Carroll P (2018) Impact of Increased Number of Biopsies on the Nature of Prostate Cancer IdentifiedJournal of Urology, VOL. 176, NO. 1, (63-69), Online publication date: 1-Jul-2006.Buskirk S, Pisansky T, Schild S, Macdonald O, Wehle M, Kozelsky T, Collie A, Ferrigni R, Myers R, Prussak K, Heckman M, Crook J, Parker A and Igel T (2018) Salvage Radiotherapy for Isolated Prostate Specific Antigen Increase After Radical Prostatectomy: Evaluation of Prognostic Factors and Creation of a Prognostic Scoring SystemJournal of Urology, VOL. 176, NO. 3, (985-990), Online publication date: 1-Sep-2006.Eggener S, Roehl K, Yossepowitch O and Catalona W (2018) Prediagnosis Prostate Specific Antigen Velocity is Associated With Risk of Prostate Cancer Progression Following Brachytherapy and External Beam Radiation TherapyJournal of Urology, VOL. 176, NO. 4, (1399-1403), Online publication date: 1-Oct-2006.MENG M, ELKIN E, LATINI D, DuCHANE J and CARROLL P (2018) TREATMENT OF PATIENTS WITH HIGH RISK LOCALIZED PROSTATE CANCER: RESULTS FROM CANCER OF THE PROSTATE STRATEGIC UROLOGICAL RESEARCH ENDEAVOR (CaPSURE)Journal of Urology, VOL. 173, NO. 5, (1557-1561), Online publication date: 1-May-2005.ANAST J, SADETSKY N, PASTA D, BASSETT W, LATINI D, DuCHANE J, CHAN J, COOPERBERG M, CARROLL P and KANE C (2018) THE IMPACT OF OBESITY ON HEALTH RELATED QUALITY OF LIFE BEFORE AND AFTER RADICAL PROSTATECTOMY (DATA FROM CaPSURE)Journal of Urology, VOL. 173, NO. 4, (1132-1138), Online publication date: 1-Apr-2005.MITCHELL J, COOPERBERG M, ELKIN E, LUBECK D, MEHTA S, KANE C and CARROLL P (2018) ABILITY OF 2 PRETREATMENT RISK ASSESSMENT METHODS TO PREDICT PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY: DATA FROM CaPSUREJournal of Urology, VOL. 173, NO. 4, (1126-1131), Online publication date: 1-Apr-2005.COOPERBERG M, PASTA D, ELKIN E, LITWIN M, LATINI D, Du CHANE J and CARROLL P (2018) THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMYJournal of Urology, VOL. 173, NO. 6, (1938-1942), Online publication date: 1-Jun-2005.PARK S, MENG M, ELKIN E, SPEIGHT J, DuCHANE J and CARROLL P (2018) ANDROGEN DEPRIVATION USE WITH EXTERNAL BEAM RADIATION FOR PROSTATE CANCER: RESULTS FROM CaPSURE™Journal of Urology, VOL. 174, NO. 5, (1802-1807), Online publication date: 1-Nov-2005. Volume 171Issue 4April 2004Page: 1393-1401 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsquality of lifeprostateprostatic neoplasmsdatabasesfactualdisease managementMetricsAuthor Information MATTHEW R. COOPERBERG More articles by this author JEANETTE M. BROERING More articles by this author MARK S. LITWIN More articles by this author DEBORAH P. LUBECK More articles by this author SHILPA S. MEHTA More articles by this author JAMES M. HENNING More articles by this author PETER R. CARROLL More articles by this author the CaPSURE INVESTIGATORS More articles by this author Expand All Advertisement PDF downloadLoading ...

Referência(s)